摘要
目的观察血必净联合西医治疗老年毛细血管渗漏综合征(CLS)的疗效及对血压、血清炎症因子的影响。方法将84例老年CLS病例随机分为观察组(44例)和对照组(40例)。对照组给予西医治疗,观察组在对照组的基础上给予血必净治疗。治疗第8天观察2组急性生理学及慢性健康状况评分系统Ⅱ(APACHEⅡ)评分、机械通气时间、重症加强护理病房(ICU)住院时间、病死率以及收缩压(SBP)、舒张压(DBP)、平均动脉压(MAP)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)的变化。结果 (1)观察组治疗第8天APACHEⅡ评分、机械通气时间、ICU住院时间、病死率均明显低于对照组,差异均有统计学意义(P均<0.05);(2)治疗第8天,2组SBP、DBP、MAP均明显上升(P均<0.05),但观察组升高更明显,2组比较差异有统计学意义(P均<0.05);(3)治疗第8天,2组CRP、TNF-α及IL-6水平均明显下降(P均<0.05),且观察组下降更明显,2组比较差异有统计学意义(P均<0.05)。结论血必净可提高老年CLS病人临床治疗效果,有稳定血压、抑制炎症反应的作用。
Objective To observe the efficacy of Xuebijing combined with western medicine and the effect on blood pressure, serum inflammatory factors in the elderly patients with capillary leak syndrome (CLS). Methods Eighty-four cases of elderly patients with CLS were randomly divided into observation group (44 cases) and control group (40 cases).Patients in control group were given western medicine, and patients in observation group were given Xuebijing injection based on the treatment of control group. APACHE Ⅱ score, mechanical ventilation time, ICU stay time, mortality rate, systolic blood pressure( SBP), diastolic blood pressure( DBP), mean arterial pressure ( MAP ), the levels of Creaction protein( CRP), tumor necrosis factor-α (TNF-α), interleukin-6(IL-6) in two groups before and after the treatment were observed and compared. Results (1)APACHE Ⅱ score, mechanical ventilation time, ICU stay time, mortality rate of the observation group after treatment were significantly lower than those of the control group ( P〈 0.05 ) ; (2) After treatment, SBP, DBP, MAP in the two groups were increased obviously ( P〈0. 05 ), especially in observation group( P〈0. 05 ). ( 3 ) The levels of CRP, TNF-α, IL-6 in the two groups after treatment were decreased obviously (P〈0.05), especially in observation group (P〈 0. 05 ). Conclusions Xuebijing can improve the clinical efficacy in elderly patients with CLS, with effect on stabilizing blood pressure and inhibiting the inflammatory reaction.
出处
《实用老年医学》
CAS
2017年第4期362-365,共4页
Practical Geriatrics